Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with recognized
variability in clinical outcome, genetic features, and cells of origin. To date, transcriptional …

Background Several gene-expression signatures can be used to predict the prognosis in
diffuse large-B-cell lymphoma, but the lack of practical tests for a genome-scale analysis has …

Background The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma
is crucial because these two types of lymphoma require different treatments. We examined …

Gene expression profiling (GEP) has stratified diffuse large B-cell lymphoma (DLBCL) into
molecular subgroups that correspond to different stages of lymphocyte development …

Purpose: Next-generation sequencing (NGS) has detailed the genomic characterization of
diffuse large B-cell lymphoma (DLBCL) by identifying recurrent somatic mutations. We set …

Purpose: Relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) is fatal in 90% of
patients, and yet little is known about its biology. Experimental Design: Using exome …

The molecular alterations underlying the pathogenesis of angioimmunoblastic T-cell
lymphoma (AITL) and peripheral T-cell lymphoma, unspecified (PTCL-u) are largely …

Signals emanating from the B‐cell receptor (BCR) promote proliferation and survival in
diverse forms of B‐cell lymphoma. Precision medicine strategies targeting the BCR pathway …

The Limits of Reductionism in Medicine: Could Systems Biology Offer an Alternative? | PLOS
Medicine Skip to main content Advertisement PLOS Medicine Browse Current Issue Journal …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer originating from mature B-
cells. Prognosis is strongly associated with molecular subgroup, although the driver …